Multiple Sclerosis Research Repository

1. “Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS”: Lorscheider J et al

-this study provides class IV evidence that for patients with SPMS, disease-modifying treatment has no beneficial effect on short-term disability progression

-SPECTRUM and IMPACT trials

-In line with the outcomes of most of the previous trials, our present study shows that, on average, the currently available anti-inflammatory drugs do not prevent relapse-unrelated disability accumulation of disability in patients with established SPMS in the short-term-our recent study showed that highly-effective immunotherapy mitigates predominantly relapse-dependent disability accrual over 11 years in patients with moderately advanced or advanced relapse-onset MS (regardless of their SPMS)